Skip to main content
Sinopharm Group Co. Ltd. logo

Sinopharm Group Co. Ltd. — Investor Relations & Filings

Ticker · 1099 ISIN · CNE100000FN7 LEI · 529900N54X78YH9JYK92 HKEX Wholesale and retail trade
Open in API
Filings indexed 1,610 across all filing types
Latest filing 2023-12-05 Proxy Solicitation & In…
Country CN China
Listing HKEX 1099

About Sinopharm Group Co. Ltd.

http://www.sinopharmholding.com

Sinopharm Group Co. Ltd. is a major state-owned enterprise recognized as the largest pharmaceutical logistics provider in Asia and a leading distributor and retailer of healthcare products. The company's core business revolves around providing comprehensive medical supply chain services, encompassing the wholesale and retail distribution of pharmaceuticals, medical devices, and general healthcare products. Sinopharm serves a broad customer base, including hospitals, primary health service institutions, and retail pharmacies. Furthermore, the Group maintains an integrated ecosystem that extends beyond distribution into the manufacturing of pharmaceuticals and chemical reagents, medical services, and industry-finance integration, positioning it as a full-spectrum service provider in the healthcare sector.

Recent filings

Filing Released Lang Actions
(1) CONTINUING CONNECTED TRANSACTIONS: 2023 PROCUREMENT FRAMEWORK AGREEMENT AND 2023 SALES FRAMEWORK AGREEMENT&#x3b; (2) DISCLOSEABLE TRANSACTION AND CONTINUING CONNECTED TRANSACTION: 2023 FINANCIAL S
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a circular from Sinopharm Group Co. Ltd. concerning multiple corporate matters including continuing connected transactions, discloseable transactions, proposed amendments to the articles of association, and a notice of an Extraordinary General Meeting (EGM). It includes detailed definitions, letters from the board, independent board committee, and independent financial adviser, and a notice convening the EGM. The content is typical of materials sent to shareholders to inform them and solicit votes on corporate matters at a general meeting. It is not a financial report, earnings release, or audit report. It is not a proxy solicitation or remuneration report specifically, but rather a circular containing information and a notice of an EGM. Given the detailed nature and the inclusion of the notice of EGM, this document fits best under the category of Proxy Solicitation & Information Statement (PSI), which covers materials sent to shareholders to provide information and request votes for meetings.
2023-12-05 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2023
Share Issue/Capital Change Classification · 95% confidence The document is a monthly return report submitted to the Hong Kong Exchanges and Clearing Limited regarding movements in securities, specifically detailing movements in authorised/registered share capital and issued shares for Sinopharm Group Co. Ltd. It includes confirmations related to share issuance and compliance with listing rules. The document is structured as a regulatory submission about share capital and share movements, not a financial report, earnings release, or management discussion. It is not a report publication announcement since it contains substantive data about share capital and share movements. The content aligns with announcements about share capital changes and share issuance confirmations. Therefore, the document fits best under the category of Share Issue/Capital Change (SHA).
2023-12-04 English
CLOSURE OF THE REGISTER OF MEMBERS
Regulatory Filings Classification · 95% confidence The document is an announcement from Sinopharm Group Co. Ltd. regarding the closure of the register of members for the purpose of holding an extraordinary general meeting (EGM) on 20 December 2023. It references previous announcements and details about proposed amendments to the articles of association and continuing connected transactions. The document specifies the dates for the register closure and instructions for shareholders to qualify for voting at the EGM. The document is short (4318 characters) and serves as a notice about the register closure and meeting arrangements rather than the meeting materials or voting results themselves. It does not contain financial data, voting results, or detailed meeting materials. Therefore, it is best classified as a Regulatory Filing (RNS) as it is a general regulatory announcement related to shareholder meeting logistics and does not fit other more specific categories like AGM Information, Declaration of Voting Results, or Proxy Solicitation.
2023-12-01 English
ANNOUNCEMENT (1) CONTINUING CONNECTED TRANSACTIONS: 2023 PROCUREMENT FRAMEWORK AGREEMENT, 2023 SALES FRAMEWORK AGREEMENT, 2023 EPC GENERAL CONTRACTING SERVICES FRAMEWORK AGREEMENT AND 2023 FACTORING S
Regulatory Filings Classification · 95% confidence The document is an announcement by Sinopharm Group Co. Ltd. regarding multiple framework agreements for continuing connected transactions and a discloseable transaction related to financial services. It discusses the terms, annual caps, and shareholder approval requirements for these agreements. The text references Hong Kong Listing Rules and details about an upcoming extraordinary general meeting to approve these transactions. The document is structured as a formal announcement of corporate transactions and shareholder meeting arrangements, not a full financial report or detailed financial statements. It is not an annual report, interim report, earnings release, or management discussion. It is also not a proxy solicitation or remuneration report. The content fits the category of a Regulatory Filing (RNS) as it is a regulatory announcement about connected transactions and related shareholder approvals under Hong Kong Listing Rules, without substantive financial data or report content. The document length (15,000 characters) and detailed transaction descriptions support this classification rather than a brief report publication announcement or a full report.
2023-11-09 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2023
Regulatory Filings Classification · 95% confidence The document is a monthly return report submitted to the Hong Kong Exchanges and Clearing Limited regarding movements in securities for Sinopharm Group Co. Ltd. It details movements in authorized and issued share capital, confirms compliance with listing rules, and provides no financial statements or earnings data. The document is regulatory in nature, reporting share capital and securities movements, but it is not an earnings release, annual report, or management report. It is not a proxy, voting result, or capital raising announcement. The document fits the category of a regulatory filing reporting share capital and securities movements under exchange rules.
2023-11-02 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2023-10-30 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.